GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Sponsor

Providence Health & Services (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05913388

Collaborator

Providence Cancer Center (Other), Providence Cancer Center, Earle A. Chiles Research Institute (Other), Galecto Biotech AB (Industry)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Melanoma Head and Neck Squamous Cell Carcinoma	Drug: GB1211 Drug: Pembrolizumab Drug: Placebo	Phase 2

Detailed Description

Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GB1211 + pembrolizumab or pembrolizumab + placebo.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

92 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Anticipated Study Start Date :

Aug 1, 2023

Anticipated Primary Completion Date :

Aug 1, 2028

Anticipated Study Completion Date :

Aug 1, 2030

Arms and Interventions

Arm	Intervention/Treatment
Experimental: GB1211 + Pembrolizumab GB1211 will be administered orally twice a day at 400mg in combination with standard pembrolizumab treatment.	Drug: GB1211 Administered orally twice daily at 400mg. Drug: Pembrolizumab Administered at a fixed dose of 200 mg every 3 weeks intravenously. Other Names: Keytruda
Placebo Comparator: Pembrolizumab Monotherapy Placebo will have the same appearance as GB1211 and administered orally twice a day in combination with standard pembrolizumab treatment.	Drug: Pembrolizumab Administered at a fixed dose of 200 mg every 3 weeks intravenously. Other Names: Keytruda Drug: Placebo Administered orally twice daily at 400mg.

Arm

Intervention/Treatment

Experimental: GB1211 + Pembrolizumab

GB1211 will be administered orally twice a day at 400mg in combination with standard pembrolizumab treatment.

Drug: GB1211

Administered orally twice daily at 400mg.

Drug: Pembrolizumab

Administered at a fixed dose of 200 mg every 3 weeks intravenously.

Other Names:

Keytruda

Placebo Comparator: Pembrolizumab Monotherapy

Placebo will have the same appearance as GB1211 and administered orally twice a day in combination with standard pembrolizumab treatment.

Drug: Pembrolizumab

Administered at a fixed dose of 200 mg every 3 weeks intravenously.

Other Names:

Keytruda

Drug: Placebo

Administered orally twice daily at 400mg.

Outcome Measures

Primary Outcome Measures

Overall response rate based on disease imaging [From the date of randomization until the date of first documented progression, assessed up to 63 weeks.]
Determine the response of Gal-3 inhibitor and pembrolizumab versus pembrolizumab monotherapy (plus placebo) in patients with metastatic melanoma or HNSCC.

Secondary Outcome Measures

Evaluation of GAL-3 Expression [Screening and Day 68]
Compare Gal-3 expression in paired biopsies after GB1211 + pembrolizumab or pembrolizumab monotherapy
Evaluation of Predictive Biomarker [Day 85]
Characterize MDSC expression over time as a predictive biomarker of response after GB1211 + pembrolizumab or pembrolizumab monotherapy
Frequency of Immune-mediated Adverse Events [From the time of informed consent to week 63]
Compare the frequency of immune-mediated adverse events after GB1211 + pembrolizumab versus pembrolizumab + placebo
Evaluation of Antiviral Immunity [Day 85]
Assess the biological activity of GB1211 + pembrolizumab and in comparison to pembrolizumab monotherapy by measuring CD4+T cells with a memory phenotype (CD3+CD4+Ki67+CD25+FoxP3-CCR7-CD45RA-CD27+CD28+/-).
Evaluation of Antiviral Immunity [Day 85]
Assess the biological activity of GB1211 + pembrolizumab and in comparison to pembrolizumab monotherapy by measuring CD8+ T cells with effector phenotype (CD3+CD8+CD28-CD95+).
Evaluation of Antiviral Immunity [Day 85]
Assess the biological activity of GB1211 + pembrolizumab and in comparison to pembrolizumab monotherapy by measuring tumor-specific T cells using autologous and/or HLA-matched tumor when available.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with unresectable or metastatic melanoma including unknown primary or mucosal melanomas. Histological confirmation of melanoma will be required by previous biopsy or cytology. Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression during or after platinum-containing chemotherapy are eligible. PD-L1 testing is not needed for OHN cancers.
Patients who have received anti-PD1 or anti-PD-L1 in the past are eligible if it has been at least 6 months since the last anti-PD-1 or PD-L1 dose, they meet all other eligibility criteria and progression of malignancy has been documented on imaging. Progression for this patient subset is defined as the appearance of one or more new metastatic sites, or a 5% or greater increase in the sum of diameter of target lesions or an unequivocal increase in non-target site. Treatment naïve melanoma patients are eligible.
Patients must be ≥ 18 years of age.
ECOG performance status of 0-2.
Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy.
No active bleeding.
Anticipated lifespan greater than 12 weeks.
Patients must sign a study-specific consent document.

Exclusion Criteria:

Patients who have previously received a galectin antagonist.
Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo.
Patients with history of autoimmune colitis.
Patients with untreated brain metastases. Patients with treated brain metastases who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.
Patients requiring other systemic oncologic therapy, including experimental therapies.
Patients who have received anti-cancer treatment within 3 weeks or 5 half-lives before first study drug dose.
Patients with Child-Pugh C hepatic impairment.
Patients with active infection requiring antibiotics.
Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
Need for steroids at greater than physiologic replacement doses. Inhaled corticosteroids are acceptable.
Laboratory exclusions (to be performed within 28 days of enrollment):
WBC < 3.0 x 109/L
Hgb < 9.0 g/dL
AST or ALT > 1.5 times ULN
Total bilirubin > 1.9 g/dL, unless due to Gilbert's Syndrome. If Gilbert's Syndrome is present by clinical history, then direct bilirubin must by < 3.0 g/dl.
Active or known history of HIV
Active or known history of Hepatitis B
Active or known history of Hepatitis C
Platelet counts < 100 x 10E9 / L (100,000/ μL) without transfusion
INR > 1.5x ULN
Inability to give informed consent and comply with the protocol. Patients must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.
Any medical condition that in the opinion of the Principal Investigator would compromise the safety or conduct of the study procedures.
Unresolved immune-mediated pneumonitis, diarrhea, elevation of hepatocellular enzymes or other toxicities requiring greater than physiological replacement doses of steroids.